Correction to: Communications Medicinehttps://doi.org/10.1038/s43856-022-00209-1, published online 06 December 2022.
The data in Table 2 were erroneously duplicated in Table 3 of this article. The correct version of Table 3 is displayed below. Table 3 has been corrected in the HTML and PDF versions of this article.
Table 3. Results obtained with the expanded drug list.
Drug | Albumin IC50 | ALT | Morphology | IF imaging | ||||
---|---|---|---|---|---|---|---|---|
Donor 1 | Donor 2 | Donor 1 | Donor 2 | Donor 1 | Donor 2 | Donor 1 | Donor 2 | |
Asunaprevir | 190 | – | >1000 | – | 1000 | – | Apoptosis | – |
Benoxaprofen | 8 | 20 | >100 | 100 | <0.1 | 100 | Apoptosis | Apoptosis |
Beta-Estradiol | >300 | – | >300 | – | >300 | – | No findings | – |
Chlorpheniramine | >300 | – | >300 | – | >300 | – | No findings | – |
Diclofenac | 384 | – | >1000 | – | 1000 | – | Apoptosis | – |
Labetalol | 26 | 40 | >100 | 100 | >100 | 100 | Apoptosis | Apoptosis |
Lomitapide | 4 | – | >1000 | – | <0.1 | – | No findings | – |
Simvastatin | <0.1 | <10 | >300 | >300 | >300 | >300 | No findings | Apoptosis |
Stavudine | >60 | 132 | 300 | >300 | 300 | 300 | No findings | Mitotoxicity |
Tacrine | 76 | >25 | >300 | >1000 | >300 | >1000 | Apoptosis | Apoptosis |
Telithromycin | 13 | – | 30 | – | 100 | – | Apoptosis | – |
Ximelagatran | 32 | >300 | 30 | >300 | 100 | 300 | No findings | No findings |
Zileuton | >100 | 210 | >100 | >300 | >100 | >300 | No findings | No findings |
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Details








1 Emulate Inc., Boston, USA (GRID:grid.511183.f) (ISNI:0000 0004 4907 3622)
2 Janssen Pharmaceuticals, Spring House, Philadelphia, USA (GRID:grid.497530.c) (ISNI:0000 0004 0389 4927)
3 Investigative Toxicology and Pathology, Abbvie, North Chicago, USA (GRID:grid.431072.3) (ISNI:0000 0004 0572 4227)
4 Harvard University, Wyss Institute for Biologically Inspired Engineering, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Harvard University, Harvard John A. Paulson School of Engineering and Applied Sciences, Cambridge, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Harvard Medical School and Boston Children’s Hospital, Vascular Biology Program and Department of Surgery, Boston, USA (GRID:grid.2515.3) (ISNI:0000 0004 0378 8438)
5 JW Scannell Analytics LTD, Edinburgh, UK (GRID:grid.2515.3)